Brittany Craiglow, MD
Associate Professor Adjunct - DermatologyCards
About
Research
Publications
2025
Guest Editor's Note
Craiglow B. Guest Editor's Note. Pediatric Dermatology 2025, 42: 4-4. PMID: 40044618, DOI: 10.1111/pde.15861.Peer-Reviewed Original ResearchSystemic Therapies for Pediatric Alopecia Areata
Kalil L, Welch D, Heath C, Craiglow B. Systemic Therapies for Pediatric Alopecia Areata. Pediatric Dermatology 2025, 42: 36-42. PMID: 40044621, DOI: 10.1111/pde.15822.Peer-Reviewed Original ResearchConceptsAlopecia areataSystemic therapyPediatric alopecia areataAutoimmune hair loss disorderJanus kinase inhibitorsHair loss disorderComorbid atopyOral minoxidilLong-term useSystemic corticosteroidsTopical therapySystemic treatmentPediatric AACase reportAdjunctive treatmentMild diseaseKinase inhibitorsImmunomodulatory medicinesTherapyExtensive involvementAdverse effectsNarrative reviewAreataPatientsTreatmentCharacterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy with Baricitinib 4-mg: Results From BRAVE-AA1 and -AA2 Trials
Senna M, Taylor S, Piraccini B, Shapiro J, Somani N, Jedynak J, Ogwu S, Buchanan A, Craiglow B, Ohyama M. Characterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy with Baricitinib 4-mg: Results From BRAVE-AA1 and -AA2 Trials. SKIN The Journal Of Cutaneous Medicine 2025, 9: s522. DOI: 10.25251/skin.9.supp.522.Peer-Reviewed Original ResearchSeverity of Alopecia ToolLoss of responseSeverity of Alopecia Tool scoreBaricitinib 4 mgLost responseMaintenance treatmentAlopecia areataLong-term maintenance therapyYears of initial treatmentWeeks of maintenance treatmentBaseline disease characteristicsSevere alopecia areataPhase 3 trialYear of treatmentPost hoc analysisBaricitinib monotherapySevere AAMaintenance therapySALT scoreMaintained responseInitial treatmentBaseline characteristicsAdjunctive therapyTreatment responseCOVID-19 infectionLow-Dose Oral Minoxidil Initiation for Patients With Hair Loss
Akiska Y, Mirmirani P, Roseborough I, Mathes E, Bhutani T, Ambrosy A, Aguh C, Bergfeld W, Callender V, Castelo-Soccio L, Cotsarelis G, Craiglow B, Desai N, Doche I, Duque-Estrada B, Elston D, Goh C, Goldberg L, Grimalt R, Jabbari A, Jolliffe V, King B, LaSenna C, Lenzy Y, Lester J, Lortkipanidze N, Sicco K, McMichael A, Meah N, Mesinkovska N, Miteva M, Mostaghimi A, Ovcharenko Y, Piliang M, Piraccini B, Rakowska A, Salkey K, Schmidt A, Shapiro J, Sibbald C, Sinclair R, Suchonwanit P, Taylor S, Tosti A, Vañó-Galván S, Wall D, Fu J. Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss. JAMA Dermatology 2025, 161: 87-95. PMID: 39565602, DOI: 10.1001/jamadermatol.2024.4593.Peer-Reviewed Original ResearchLow-dose oral minoxidilOral minoxidilExpert consensus statementTopical minoxidilHair lossPediatric patientsConsensus statementModified Delphi processDelphi consensus processEfficacy of topical minoxidilResults of small studiesInternational expert consensus statementsTreating pediatric patientsAdverse effect profileLong-term safetyOff-label useSpecialty consultationOff-label prescribingDelphi processSurvey roundsEvidence-based dataConsensus processExpert panelSublingual minoxidilThird round
2024
Achievement of No-to-minimal Itch and Sleep Improvement with Tapinarof Cream 1% Once Daily in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age with Atopic Dermatitis
Simpson E, Siri D, Chovatiya R, Shahriari M, Burnette A, Craiglow B, Brown P, Tallman A. Achievement of No-to-minimal Itch and Sleep Improvement with Tapinarof Cream 1% Once Daily in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age with Atopic Dermatitis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s459. DOI: 10.25251/skin.8.supp.459.Peer-Reviewed Original ResearchPP-NRSPatient Oriented Eczema MeasurePhase 3 trialAtopic dermatitisWeek 8Eczema Area and Severity Index scorePeak Pruritus Numerical Rating ScaleBody surface area involvementPruritus Numerical Rating ScaleInvestigator's Global AssessmentNumerical rating scaleSurface area involvementSeverity index scoreSleep disturbanceAnalyzed post hocSleep improvementImprovement of sleepTapinarof creamEvaluate sleep disturbancesSuperior efficacySleep disturbance scoresArea involvementTapinarofItchingGlobal assessmentWorldwide Clinical and Real-World Exposure to Baricitinib
Vleugels R, Craiglow B, Mostaghimi A, Olsen E, Sontag A, Denning K, Somani N, Hordinsky M. Worldwide Clinical and Real-World Exposure to Baricitinib. SKIN The Journal Of Cutaneous Medicine 2024, 8: s501. DOI: 10.25251/skin.8.supp.501.Peer-Reviewed Original ResearchLength of therapyClinical trialsAtopic dermatitisTreated with baricitinibAverage length of therapyAge 2 yearsJuvenile idiopathic arthritisYears of ageMonths of ageBaricitinib doseAverage daily doseYrs of agePediatric patientsAcute infectious diseaseDaily doseCOVID-19 infectionAlopecia areataJAK inhibitorsHospitalized patientsIdiopathic arthritisBaricitinibPatientsBlind trialRheumatoid arthritisDisease statesACHIEVEMENT OF ITCH-FREE STATE AND SLEEP IMPROVEMENT WITH TAPINAROF IN TWO PIVOTAL ATOPIC DERMATITIS TRIALS
Simpson E, Siri D, Chovatiya R, Shahriari M, Burnette A, Craiglow B, Brown P, Tallman A. ACHIEVEMENT OF ITCH-FREE STATE AND SLEEP IMPROVEMENT WITH TAPINAROF IN TWO PIVOTAL ATOPIC DERMATITIS TRIALS. Annals Of Allergy Asthma & Immunology 2024, 133: s9. DOI: 10.1016/j.anai.2024.08.055.Peer-Reviewed Original ResearchPatient Oriented Eczema MeasurePP-NRSAtopic dermatitisWeek 8Sleep disturbancePeak Pruritus Numerical Rating ScalePruritus Numerical Rating ScaleNumerical rating scaleAnalyzed post hocStatistically significant improvementEvaluate sleep disturbancesRating ScaleSleep improvementTapinarofWeek 1Itch reductionScore improvementTreatment groupsBaseline scoresItchingWeeksPost-hocSleepPatientsOutcomesPublisher Correction: Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
Craiglow B, Lee Y, Vañó-Galván S, Egeberg A, Dutronc Y, Durand F, Pierce E, Yu G, Chen Y, Mostaghimi A. Publisher Correction: Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib. Dermatology And Therapy 2024, 14: 3193-3193. PMID: 39404927, PMCID: PMC11557806, DOI: 10.1007/s13555-024-01265-2.Peer-Reviewed Original ResearchBH04 A global survey to assess practice of laboratory testing in alopecia areata by hair specialists
O’Connor C, Asfour L, Bokhari L, Cotsarelis G, Cotter C, Craiglow B, Cutlar L, Dhurat R, Dlova N, Doche I, Donovan J, Eisman S, Melo D, Harries M, Hordinsky M, Kazmi A, King B, Meah N, Ohyama M, Ovcharenko J, Primez R, Piraccini B, Rudnicka L, Corralo D, Shapiro J, Sinclair R, Smith B, Starace M, Galvan S, Wang K, York K, McDonald I, Wall D. BH04 A global survey to assess practice of laboratory testing in alopecia areata by hair specialists. British Journal Of Dermatology 2024, 191: i74-i75. DOI: 10.1093/bjd/ljae090.151.Peer-Reviewed Original ResearchLiver function testsFunction testsHIV testingHepatitis BLipid testingAlopecia areataSeverity of Alopecia ToolScreening bloodHair disordersRenal function testsRisk of cardiovascular diseaseJanus kinase inhibitorsDermatology Life Quality IndexJanus kinaseBritish Association of DermatologistsLife Quality IndexLaboratory testsHair loss disorderSystemic therapyThyroid testsIdentification of comorbiditiesImmune-mediatedRenal functionThyroid diseaseAssociation of DermatologistsImprovement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
Craiglow B, Lee Y, Vañó-Galván S, Egeberg A, Dutronc Y, Durand F, Pierce E, Yu G, Chen Y, Mostaghimi A. Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib. Dermatology And Therapy 2024, 14: 1959-1968. PMID: 38904749, PMCID: PMC11265044, DOI: 10.1007/s13555-024-01208-x.Peer-Reviewed Original ResearchSymptoms of anxietyQuality of lifeDomain scoresHealth-related quality of lifeMeasures of quality of lifeMeasures of HRQoLHealth-related qualityBaricitinib 2 mgSALT scoreBaricitinib 4 mgPsychosocial distressAssociated with improvementsHair regrowthAA scaleMethodsThis post hoc analysisHRQoLDose of baricitinibInterquartile rangePhase III trialsResultsIn totalSevere alopecia areataPost hoc analysisDisease associated with high ratesDepressionScores
News
News
Get In Touch
Contacts
Mailing Address
Dermatology
PO Box 208059
New Haven, CT 06520-8059
United States